We observed that PD-1 blockade was able to markedly extend the survival of ORFV pretreated mice (Fig. 6b), which further supported that oncolytic ORFV can harness GSDME, recruit CTLs and further remodel tumor immune microenvironment. Here, PDCD1 is linked to neoplasm.